5MULLER R H. Dispersions for the formulation of slightly or poorly soluble agents[ P]. US :2003/0059470 A1, 2003-3-27.
6MULLER R H, SCHMIDT S, BUTTLE I, et al. SolEmuls-novel technology for the formulation of iv emulsions with poorly soluble drugs[J]. Int JPharm, 2004, 269 (2) :293-302.
7KECK C M, MULLER R H. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation [ J ]. Eur J Pharm Biopharm, 2006, 62 ( 1 ) :3-16.
8MULLER R H, BECKER R, KRUSS B, et al. Pharmaceutical nanosuspensions for medicament administration as systems with increased saturation solubility and rate of solution [ P ]. US: 5858410,1999-01-12.
9KRAUSE K P, KAYSER O, MADER K, et al. Heavy metal contamination of nanosuspensions produced by high-pressure homogenisation[ J]. Int J Pharm,2000, 196 (2) :169-172.
10AKKAR A, MULLER R H. Formulation of intravenous carbamazepine emulsions by SolEmuls technology[ J]. Eur J Pharm Biopharm, 2003,55 (3) :305-312.
3[5]Pather SI, Neau SH, Pather S. A Comparison of two quality assessment methods for emulsions [J] . Journal of pharmaceutical and BionediealAnalysis, 1995, 13 (10): 1283
4[3]Chansiri C, Lyons RT, Patel MV, et al. Effect of Surface Charge on the Stability of Oil/Water Emulsions during Steam Sterilization [J] . Journalof Pharmaceutical Sciences, 1999, 88(4): 454
5[4]Driscoll DF, Etzler F, Barber TA, et al. Physicochemical assessments of parenteral lipid emulsions: light obscuration ver sus laser diffraction [J] . International Journal of Pharma ceutics, 2001, 219 (1～2): 21
6Gabetta B, Bombardelli E, Pifferi G. Complexes of flavanolignans with phospholipids, preparation thereof and associated pharmaceutical compositions [P]. EP: 209038,1987-01-21 (CA 1987, 107:121086).
